A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

Part of paid clinical trials in Glendale, California.

Sponsor
Hoffmann-La Roche
Study ID
NCT07588100
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RO7663498 — DRUG
    Participants will receive RO7663498 as per the schedule defined in the protocol.

Study Details

This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).

Key Dates

Start date
Jun 22, 2026
Status verified
Jun 2026
Primary completion
Dec 30, 2027
Completion
Dec 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Participants will receive RO7663498.
  • Experimental: Cohort 2
    Participants will receive RO7663498.
  • Experimental: Cohort 3
    Participants will receive RO7663498.
  • Experimental: Cohort 4
    Participants will receive RO7663498.

Primary Outcome Measure

Percentage of Participants With Ocular Adverse Events (AEs) [ Time Frame: Up to Week 20 ]

Central Contacts

  • Reference Study ID Number: BP46156 https://forpatients.roche.com/
    888-662-6728 (U.S. Only)
    [email protected]
  • Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Locations (1)

FacilityCityStateZIPSite coordinators
Global Research ManagementGlendaleCalifornia91204-

Find similar trials in Glendale, CA

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Global Research Management· Glendale, CA

Related Studies